With over 20 years of experience in life sciences, specializing in early-stage innovation and market strategy. Previously with Urogen Pharma (NASDAQ: URGN), he holds a B.Sc. in Life Sciences from Ben-Gurion University.

With over 25 years of experience in medical operations and biotech, previously with LBT Laser Beam Therapeutics, he holds a Ph.D. in Health Systems Management from Ben-Gurion University.

With over 16 years of financial experience in biotech and pharmaceuticals. Previously with OWC Pharma (OTCQB: OWCP) and Rosetta Genomics (NASDAQ: ROSG), she holds a B.A. in Economics and Accounting from Ruppin Academic College.

A pioneer in regenerative medicine, trained at MIT under Prof. Robert Langer. He founded Tel Aviv University’s Tissue Engineering Lab and leads research in nanotechnology-based tissue regeneration.

An award-winning researcher and recipient of the Young and Promising Bio-Medical Researcher Rappaport Prize (2018), the Juludan Foundation Research Award (2018), and the Da Vinci Award (2023).

An expert in biotechnology with experience at CollPlant (NASDAQ: CLGN) and Cellect (NASDAQ: APOP). She holds a Ph.D. in Biotechnology Engineering from Ben-Gurion University.

Member of the ‘Best Practice Task Force’ focused on the standardization of iPSC-based therapy, led by ISSCR (International Society for Stem Cell Medicine)

A leader in biotechnology operations with expertise in regenerative medicine and product development. Previously with CollPlant (NASDAQ: CLGN), she holds an M.Sc. in Materials Engineering & Nanotechnology from Tel Aviv University.

With over 15 years of experience in cell and gene therapy, spanning clinical, regulatory, and business aspects. Previously with Emendo and Gamida Cell (NASDAQ: GMDA), she holds an M.Sc. in Medical Research and an M.B.A. in Finance & Marketing from the Hebrew University.

Brings over 15 years of QA and GMP experience in cell therapy and biologics. Previously held roles at BrainStorm Cell Therapeutics (NASDAQ: BCLI), Teva Pharmaceuticals (NYSE: TEVA), and Cognate BioServices (acquired by Charles River Laboratories, NYSE: CRL). She holds an M.Sc. in Medical Sciences and a B.Sc. in Biology from Tel Aviv University.

Doron serves as the chairman and a director in a variety of technology companies, mainly in medical device companies.
In the past, Doron served as the CEO of Elron (Nasdaq: ELRNF, TASE: ELRN) and as the chairman and director of Given Imaging (previously traded at Nasdaq: GIVN; TASE: GIVN) until it was sold to Covidien (now Medtronic) for approximately USD 1 billion.

Neomi Enoch, CPA, MBA Neomi is a business consultant, bringing a vast experience as a CFO in global companies traded at NASDAQ and Tel Aviv stock exchange.

Neomi led the IPO of Parter communication at NASDAQ, and The IPO of Mul-T-Lock in Tel Aviv Stock Exchange and raised funds from capital market as CFO of Meuhedet HMO and Supesal Ltd.

Neomi serves as a director at Mekorot Water Company, Kalil industries Ltd, Exel solutions group and S.R. Accord Ltd

Neomi is a CPA holds an M.B.A from Bradford University, cum laud and B.A from Tel Aviv University.

Stanley Hirsch is a biotech and pharma CEO and Board Director with significant experience across biopharmaceutical and agricultural biotech fields.  He has extensive executive and board level experience in private and publicly listed companies on US and UK exchanges, direct experience raising capital and leading Mergers & Acquisitions.

Suzana Nahum-Zilberberg is a seasoned executive with a vast managerial and leadership experience in the healthcare industry across global companies and early-stage companies. With financial expertise and experience as a board member in various companies.

Ms. Nahum-Zilberberg is a strategic advisor and the Chairman of The Activity Based Therapy (ABT) Center Foundation for Neurorehabilitation. She served as the CEO of BioLight Life Sciences Ltd. (BOLT/TASE) between the years 2011-2020, Prior to joining BioLight, Ms. Nahum-Zilberberg held several senior positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO.

Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and a M.B.A. degree, both from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.

With over 25 years of experience in medical operations and biotech, previously with LBT Laser Beam Therapeutics, he holds a Ph.D. in Health Systems Management from Ben-Gurion University.

Lori Confino is a well-known and highly respected attorney in the hi-tech and biotech industries. Maintaining a clear view of all the shades and nuances that make up this complex world, Lori brings practical business sense to corporate and commercial transactions. Lori has over three decades of experience in corporate and commercial transactions with an emphasis on venture capital and private equity investment transactions, alongside extensive expertise guiding and advising entrepreneurs and early-stage start-ups from first seed financing, via a full range of day-to-day legal services through to the acquisition, merger or initial public offering and beyond.

A pioneer in regenerative medicine, trained at MIT under Prof. Robert Langer. He founded Tel Aviv University’s Tissue Engineering Lab and leads research in nanotechnology-based tissue regeneration.

An award-winning researcher and recipient of the Young and Promising Bio-Medical Researcher Rappaport Prize (2018), the Juludan Foundation Research Award (2018), and the Da Vinci Award (2023).

Prof. Harel is Director of the Spine Surgery and Spine Radiosurgery Division at Sheba Medical Center, one of the world’s top-ranked hospitals. He is an expert in minimally invasive spine surgery, spinal oncology, and radiosurgery, and was named among Israel’s top spine surgeons by Forbes magazine.

Trained at Sheba and the Cleveland Clinic, Prof. Harel has led the introduction of advanced techniques such as Novalis-based spine radiosurgery for treating spinal tumors and metastases. He is also a senior lecturer at Tel Aviv University and an active contributor to clinical research, with publications in leading journals on spinal oncology, imaging, and surgical innovation.

Dr. Michael G. Fehlings is a Professor of Neurosurgery at the University of Toronto and Vice Chair of Research in the Department of Surgery. He serves as a Neurosurgeon at Toronto Western Hospital and holds the Robert Campeau Foundation / Dr. C.H. Tator Chair in Brain and Spinal Cord Research at the University Health Network.

Internationally recognized as a leading expert in spinal cord injury (SCI), Dr. Fehlings specializes in complex spine surgery and translational research aimed at enhancing repair and regeneration of the injured central nervous system. His work has significantly advanced the understanding of SCI pathophysiology and treatment.

Dr. Fehlings has authored over 1,100 peer-reviewed publications and holds numerous patents related to spinal cord injury therapies. His research encompasses neuroprotection, stem cell-based regeneration, and the development of clinical practice guidelines for SCI management.

His contributions have been recognized with several prestigious awards, including the Reeve-Irvine Medal, the Olivecrona Award from the Karolinska Institute, and the Henry Farfan Award from the North American Spine Society.

Dr. Theodore is a Professor of Neurosurgery and the director of the Johns Hopkins Neurosurgical Spine Center. He is one of the world recognized expert in brain and spinal cord injury, minimally invasive spine surgeries and robotics.

Dr. Theodore has written or co-authored 30 book chapters, over 180 peer-reviewed journal articles and is co-holder of 10 patents for medical devices and procedures. His research focuses on trauma, spinal cord injuries, robotics and developing an understanding of the genetic and molecular basis of spinal diseases.

Image: Johns Hopkins Medicine

Dr. Ruchi Sharma, Senior Researcher at the National Institutes of Health (NIH), an expert in the manufacturing of induced pluripotent stem cells (iPSCs) in regenerative medicine and the development of cellular therapies.

Dr Von Keutz is the Chairman of the Advisory Board of the Fraunhofer Institute of Toxicology and Experimental Medicine (Hannover, Germany); Member of the Executive Council at Center of Healthcare Innovation (US); Member of the Advisory Committee for Pharmacologically Active Substances and Veterinary Drugs of the German Federal Institute for Risk Assessment; Member of the CAAT Advisory Board (Europe); Member of the Industrial Advisory Board (IAB) of the European Organ-on-Chip Society (EUROoCS).

Dr Wollowick is the Sr. Director of Business Development at Stryker Spine. At Stryker, Adam is focusing on mergers and acquisitions and also has responsibility for the Spine Division’s Strategy and Business Intelligence functions.

Dr. Wollowick is board-­certified by the American Board of Orthopedic Surgery. He is a member of the American Academy of Orthopedic Surgeons, the North American Spine Society and the Scoliosis Research Society.

Adam worked as an attending surgeon in the Department of Orthopedic Surgery at Montefiore Medical Center and held the title of Assistant Professor of Orthopaedic Surgery at the Albert Einstein College of Medicine, Bronx, NY, served as the Assistant Residency Program Director and was the Director of Spinal Research.

His award-­winning research has been presented nationally and internationally at major orthopaedic and spine society meetings and has been published in peer-­reviewed journals.

Dr. Wollowick received his MD in 2001 with Special Distinction in Research from the Albert Einstein College of Medicine, Bronx, NY. He completed a Masters of Business Administration in 2014 from the Yale School of Management, with a focus on Leadership in Healthcare Management.